Abstract
MicroRNAs (miRNAs) can function as either tumor suppressors or oncogenes. This study explores the role of miR-675 in ovarian cancer (OC) using in vitro OC cell lines and an in vivo orthotopic mouse model. We demonstrate that miR-675 expression inhibits primary tumor growth and metastasis by targeting TGFβ1, suppressing epithelial to mesenchymal transition (EMT), and attenuating the TGFβ signaling pathway. Functional assays revealed significant inhibition of cell proliferation, migration, and invasion by miR-675. In addition, miR-675 synergistically enhanced the apoptotic effect of paclitaxel and carboplatin, suggesting potential for combination therapy of miRNA-675 with chemotherapeutic agents. In vivo studies using orthotopic injection of miR-675 expressing and control OC cells in NSG mice demonstrated significant inhibition of primary OC growth and metastasis. These findings indicate that miR-675 is a promising therapeutic target for OC treatment.